Novel bisbenzimidazoles with antileishmanial effectiveness

Bioorganic and Medicinal Chemistry Letters

Volumn 18, Issue 8, 2008, Pages 2658-2661

  Mayence, Annie ^a   Pietka, Aurélie ^b   Collins, Margaret S ^c,d   Cushion, Melanie T ^c,d   Tekwani, Babu L ^e   Huang, Tien L ^a   Vanden Eynde, Jean Jacques ^a,b  

^a XAVIER UNIVERSITY OF LOUISIANA   (United States)

^b UNIVERSITY OF MONS   (Belgium)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

^d UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

^e UNIVERSITY OF MISSISSIPPI   (United States)

Author keywords

Bisbenzamidine; Bisbenzimidazole; Human African trypanosomiasis; Leishmaniasis; Pentamidine; Pneumocystis carinii pneumonia

Indexed keywords

ANTILEISHMANIAL AGENT; BENZIMIDAZOLE DERIVATIVE; PENTAMIDINE;

ANIMAL CELL; ANTIPROTOZOAL ACTIVITY; ARTICLE; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG EFFICACY; DRUG SCREENING; IC 50; IN VITRO STUDY; LEISHMANIA DONOVANI; NONHUMAN; PNEUMOCYSTIS CARINII; TRYPANOSOMA RHODESIENSE; VERO CELL;

ANIMALS; ANTIPROTOZOAL AGENTS; BISBENZIMIDE; LEISHMANIA DONOVANI; MOLECULAR STRUCTURE; PNEUMOCYSTIS CARINII; STRUCTURE-ACTIVITY RELATIONSHIP; TRYPANOSOMA BRUCEI BRUCEI;

LEISHMANIA DONOVANI; PNEUMOCYSTIS CARINII; TRYPANOSOMA BRUCEI RHODESIENSE;

EID: 41849100009     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2008.03.020     Document Type: Article

References (28)

1. Pinto D.J., Orwat M.J., Wang S., Fevig J.M., Quan M.L., Amparo E., Cacciola J., Rossi K.A., Alexander R.S., Wong P.C., Knabb R.M., Luettgen J.M., Aungst B.J., Wright M., Jona J.A., Wexler R.R., and Lam P.Y.S. J. Med. Chem. 44 (2001) 566
2. Soeiro M.N.C., De Souza E.M., Stephens C.E., and Boykin D.W. Expert Opin. Investig. Drugs 14 (2005) 957
3. Thomas Jr. C.F., and Limper A.H. N. Eng. J. Med. 350 (2004) 2487
4. D'Silva C. Drugs Fut. 32 (2007) 149
5. Croft S.L., and Yardley V. Curr. Pharm. Des. 8 (2002) 319
6. Jones H.E., Blundell G.K., Tidwell R.R., Hall J.E., Farr S.J., and Richards R.J. Toxicology 80 (1993) 1
7. Boykin D.W., Kumar A., Spychala J., Zhou M., Lombardy R., Wilson W.D., Dykstra C.C., Jones S.K., Hall J.E., Tidwell R.R., Laughton C., Nunn C.M., and Neidle S. J. Med. Chem. 38 (1995) 912
8. Cushion M.T., Walzer P.D., Ashbaugh A., Rebholz S., Brubaker R., Vanden Eynde J.J., Mayence A., and Huang T.L. Antimicrob. Agents Chemother. 50 (2006) 2337
9. Walzer, P.; Cushion, M. T.; Mayence, A.; Huang, T. L.; Vanden Eynde, J. J. WO Patent 2006021833, 2006.
10. Walzer P., Cushion M.T., Mayence A., Huang T.L., and Vanden Eynde J.J. Chem. Abstr. 144 (2006) 333447
11. Huang T.L., Bacchi C.J., Kode N.R., Zhang Q., Wang G., Yartlet N., Rattendi D., Londono I., Mazumder L., Vanden Eynde J.J., Mayence A., and Donkor I.O. Int. J. Antimicrob. Agents 30 (2007) 555
12. Mayence A., Vanden Eynde J.J., LeCour Jr. L., Walker L.A., Tekwani B.L., and Huang T.L. Eur. J. Med. Chem. 39 (2004) 547
13. Preston P.N. Chem. Rev. 74 (1974) 279
14. Ridley H.F., Spickett R.G., and Timmis G.M. J. Heterocycl. Chem. 2 (1965) 1965
15. Paglietti G., Pirisi M., Loriga M., Grella G., Sparatore F., Satta M., and Manca P. Farmaco Ed. Sci. 43 (1988) 215
16. Maquestiau A., Berte L., Mayence A., and Vanden Eynde J.J. Synth. Commun. 21 (1991) 2171
17. Jaunin R., and Stoll A. Helv. Chim. Acta 43 (1960) 1864
18. Donahoe H.B., Benjamin L.E., Fennoy L.V., and Greiff D. J. Org. Chem. 26 (1961) 474
19. 2: MW experimental: m/z 489.2275; MW calculated: m/z 489.2291. Mp (°C): >300 °C. Yield: 94%.
20. Gambari R., and Nastruzzi C. Biochem. Pharmacol. 47 (1994) 599
21. Beerman T.A., McHugh M.M., Sigmund R., Lown J.W., Rao K.E., and Bathini Y. Biochem. Biophys. Acta 1131 (1992) 53
22. Hildebrandt E., Boykin D.W., Kumar A., Tidwell R.R., and Dykstra C.C. J. Eukaryotic Microbiol. 45 (1998) 112
23. Stewart M.L., Boussard C., Brun R., Gilbert I.H., and Barrett M.P. Antimicrob. Agents Chemother. 49 (2005) 5169
24. Reported values are means of 2-4 determinations.
25. 10 organism nuclei with the vast majority (about 95%) of the life cycle forms present as trophic forms with the remainder (about 5%) being composed of cysts. P. carinii preparations were evaluated for microbial contamination, ATP content, karyotype, and host cell content prior to use in the ATP assay. See,. Cushion M.T., Walzer P.D., Collins M.S., Rebholz S., Vanden Eynde J.J., Mayence A., and Huang T.L. Antimicrob. Agents Chemother. 48 (2004) 4209
26. 3 bloodstream-form trypomastigotes of the strain Trypanosoma brucei rhodesiense STIB 900, which is known to be susceptible to all currently drugs. After 3 days of incubation, parasite growth is assessed fluorimetrically after the addition of resazurin. Fluorescence is measured after 24 h at 37 °C. See, http://www.who.int/tdr/grants/workplans/pdf/.
27. 6 cells/ml). Controls with corresponding dilutions of DMSO indicated that growth of the parasite was not altered under those experimental conditions. The plates were incubated at 26 °C for 72 h and growth of Leishmania promastigotes was determined by Alamar blue assay. See,. Mikus J., and Steverding D. Parasitol. Int. 48 (2000) 265
28. The compounds were tested on Vero cells (monkey kidney fibroblast) by a Neutral Red assay. See,. Babich H., and Borenfreund E. Appl. Environ. Microbiol. 57 (1991) 2101